Kura Oncology/$KURA
Kura Oncology shares are trading higher after announcing positive Phase 2 data for ziftomenib in newly diagnosed AML mutant patients and an upcoming FDA Priority Review.
2 hours ago·Lightyear AI
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Kura Oncology
Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The company's pipeline consists of small molecule drug candidates targeting cancer signaling pathways.
Ticker
$KURA
Sector
Primary listing
Industry
Biotechnology
Headquarters
Employees
192
ISIN
US50127T1097
Website
Kura Oncology Metrics
BasicAdvanced
$485M
-
-$2.09
0.50
-
Price and volume
Market cap
$485M
Beta
0.5
52-week high
$23.48
52-week low
$5.41
Average daily volume
1.3M
Financial strength
Current ratio
8.068
Quick ratio
7.934
Long term debt to equity
4.261
Total debt to equity
5.311
Interest coverage (TTM)
-126.91%
Profitability
EBITDA (TTM)
-202.588
Gross margin (TTM)
-157.46%
Net profit margin (TTM)
-267.52%
Operating margin (TTM)
-299.22%
Effective tax rate (TTM)
-1.25%
Revenue per employee (TTM)
$350,000
Management effectiveness
Return on assets (TTM)
-19.60%
Return on equity (TTM)
-41.84%
Valuation
Price to revenue (TTM)
7.169
Price to book
1.24
Price to tangible book (TTM)
1.24
Price to free cash flow (TTM)
4.409
Free cash flow yield (TTM)
22.68%
Free cash flow per share (TTM)
127.02%
Growth
Earnings per share change (TTM)
-4.14%
3-year earnings per share growth (CAGR)
1.58%
What the Analysts think about Kura Oncology
Analyst ratings (Buy, Hold, Sell) for Kura Oncology stock.
Bulls say / Bears say
Kura Oncology has submitted a New Drug Application (NDA) for ziftomenib, a menin inhibitor, for the treatment of relapsed or refractory NPM1-mutant acute myeloid leukemia (AML), marking a significant regulatory milestone. (gurufocus.com)
The company achieved a $45 million milestone payment from its collaboration with Kyowa Kirin, enhancing its financial position. (gurufocus.com)
Kura Oncology maintains a strong cash position with $703.2 million in cash, cash equivalents, and short-term investments, providing sufficient capital to fund its ziftomenib AML program through commercialization. (gurufocus.com)
BTIG downgraded Kura Oncology's stock rating to Neutral, citing concerns over the recent KOMET-001 study results for ziftomenib, including lack of clear competitive differentiation and safety and efficacy data. (investing.com)
Research and development expenses increased to $56 million in Q1 2025 from $36.3 million in Q1 2024, indicating rising costs. (gurufocus.com)
The company reported a net loss of $57.4 million for Q1 2025, compared to a net loss of $49.5 million in Q1 2024, reflecting ongoing financial challenges. (gurufocus.com)
Data summarised monthly by Lightyear AI. Last updated on 7 Jun 2025.
Kura Oncology Financial Performance
Revenues and expenses
Kura Oncology Earnings Performance
Company profitability
Kura Oncology News
AllArticlesVideos
Kura Oncology and Kyowa Kirin Report Positive Updated Combination Data for Ziftomenib in Newly Diagnosed AML at 2025 European Hematology Association Congress
GlobeNewsWire·3 weeks ago
Kura Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
GlobeNewsWire·4 weeks ago
Kura Oncology and Kyowa Kirin Report Positive Pivotal Ziftomenib Monotherapy Data at 2025 ASCO Annual Meeting
GlobeNewsWire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Kura Oncology stock?
Kura Oncology (KURA) has a market cap of $485M as of July 02, 2025.
What is the P/E ratio for Kura Oncology stock?
The price to earnings (P/E) ratio for Kura Oncology (KURA) stock is 0 as of July 02, 2025.
Does Kura Oncology stock pay dividends?
No, Kura Oncology (KURA) stock does not pay dividends to its shareholders as of July 02, 2025.
When is the next Kura Oncology dividend payment date?
Kura Oncology (KURA) stock does not pay dividends to its shareholders.
What is the beta indicator for Kura Oncology?
Kura Oncology (KURA) has a beta rating of 0.5. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.